Valproate‐associated hair abnormalities: Pathophysiology and management strategies
| Autor: | Samir Kumar Praharaj, Ravindra N Munoli, Suma T Udupa, Sivapriya Vaidyanathan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Valproic Acid
medicine.medical_specialty Alopecia Areata integumentary system business.industry Hyperandrogenism medicine.disease Dermatology Pathophysiology Telogen effluvium Psychiatry and Mental health Hair loss Neurology Minoxidil medicine Humans Agomelatine Pharmacology (medical) Neurology (clinical) business Adverse effect Hair medicine.drug |
| Zdroj: | Human Psychopharmacology: Clinical and Experimental. 37 |
| ISSN: | 1099-1077 0885-6222 |
| Popis: | Objective To review the literature on valproate-associated hair abnormalities and the available treatment options. Methods We searched PubMed and Google Scholar with keywords including "valproate", "valproic acid", "hair", "alopecia", and "effluvium," supplemented with hand search from cross-references. We included all types of studies including case reports in this review. Results The pathophysiology of hair loss includes telogen effluvium, biotin, mineral deficiency, and possibly hyperandrogenism. Diagnosis is based on history of hair loss or abnormalities following valproate treatment, and is confirmed by use of simple clinical tests such as pull test and modified wash test. Treatment involves reassurance and advice on hair care, and if possible drug discontinuation or dose reduction. Medications such as biotin and other vitamins with minerals supplementation is effective for most individuals with hair loss. Other treatment options are agomelatine, topical valproate or minoxidil, though these lack evidence. Conclusion Hair abnormalities with valproate are common, benign adverse effects, and management includes general measures and specific treatment options. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text